FABP4 and prostate neoplasm: We chose to inhibit FABP4 based on our previous studies demonstrating upregulation of this lipid transporter in prostate tumor cells exposed to marrow adipocytes, and the apparent efficacy of BMS309403 in inhibiting prostate tumor cell invasion in the 2D Boyden chamber assay (5).